Clinical study of long-term vaccinations with MAGE-A4 peptide

Clinical study of long-term vaccinations with MAGE-A4 peptide - Clinical study of long-term vaccinations with MAGE-A4 peptide

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015639

Enrollment

Registered

2014-11-10

Start date

2014-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

esophegeal cancer, ovarian cancer

Interventions

SQ administration of MAGE-A4 peptide(mixuture with IFA)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: # Completed cases of "clinical trial of ex vivo expanded autologous T lymphocytes transfer" or MAGE-A4-TCR gene-transduced T lymphocytes transfer" # Performance Status with 0 to 2 # Obtained a written informed consent

Exclusion criteria

Exclusion criteria: # Mental illness or drug dependency affecting informed consent # Pregnant, lactating, or possiblly pregnant women, or willing to be pregnant, or willing male partner, except having cryopreseved sperm # Lasting less than four weeks from the previous enrollment to clinical trials 11.Inappropriate for study entry judged by an attending physician

Design outcomes

Primary

Measure	Time frame
safety	—

Secondary

Measure	Time frame
immune responses long-term prognosis	—

Countries

Japan

Contacts

Public ContactShinichi Kageyama

Mie University Graduate School of Medicine Immuno-Gene Therapy

kageyama@clin.medic.mie-u.ac.jp059-231-5187

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026